in overweight and obese patients wi

in overweight and obese patients with type 2 diabetes.However, it is not always powerful enough to produceacceptable glucose levels.a-Glucosidase inhibitors are a recently developedalternative class of antihyperglycaemic agents whichdelay carbohydrate digestion and absorption and lowerblood glucose peaks after a meal [3]. Substantialevidence supports their use as monotherapy or adjuncttherapy for poorly controlled type 2 diabetes [4±10].Miglitol, the ®rst pseudomonosaccharide a-glucosidaseinhibitor, has been found to give comparable glycaemiccontrol to sulphonylureas in type 2 diabetes of recentonset [10]. The study reported here was carried out toinvestigate the ef®cacy and safety of miglitol vs. placeboin improving glycaemic control in type 2 diabeticoutpatients inadequately controlled with diet andmetformin therapy.Materials and MethodsStudy Design and PatientsThis international, multicentre, double-blind, randomized, placebo-controlled and parallel group studyenrolled outpatients from Europe and Israel. Patientswere screened during routine visits to the diabetologist.Eligible patients were male or female outpatients, agedbetween 30 and 75, who had been diagnosed with type 2diabetes mellitus for at least 1 year and whose diabeteswas inadequately controlled by diet and metformintaken at a stable dose for at least 3 months. Patients wererequired to have HbA1c, >7.5 and